Want to see BIO full AI Analyst Report?
Revenue by Segment
Analyzes income from different business areas, highlighting which segments drive growth and profitability, and where the company might focus future efforts.Clinical Diagnostics is the company’s ballast—relatively stable and recently stronger on quality systems and immunohematology—while Life Science has been drifting lower as consumables and process‑chromatography weakness offset ddPCR instrument momentum. ‘Other Operations’ has effectively been wound down. Management’s guidance and the $11M Middle East drag reinforce near‑term revenue and margin pressure, so upside depends on ddPCR consumable pull‑through and Diagnostics’ quality‑controls growth translating into durable recurring revenue despite cautious full‑year guidance.
Date | Other Operations | Life Science | Clinical Diagnostics |
|---|---|---|---|
Jun 30, 2026 | $0.00 | $252.00M | $399.00M |
Mar 31, 2026 | $0.00 | $228.50M | $363.60M |
Dec 31, 2025 | $0.00 | $267.90M | $425.30M |
Sep 30, 2025 | $0.00 | $261.80M | $391.20M |
Jun 30, 2025 | $0.00 | $262.80M | $388.80M |
Mar 31, 2025 | $0.00 | $228.60M | $356.80M |
Dec 31, 2024 | -$100.00K | $275.00M | $392.60M |
Sep 30, 2024 | $0.00 | $260.90M | $388.80M |
Jun 30, 2024 | $100.00K | $250.50M | $387.90M |
Mar 31, 2024 | $500.00K | $241.70M | $368.60M |